Last Thursday the Supreme Court of California decided in the Cipro ase , holding that reverse payment, or “pay-for-delay,” settlements can be challenged as unreasonable restraints on trade.
In so doing, it followed the U.S. Supreme Court’s 2013 decision in Federal Trade Commission v. Actavis. But the California court went a step further. It laid out a “structured rule of reason” test for assessing when pay-for-delay settlements are anticompetitive.
Reverse payment settlements are used to dispose of challenges brought by would-be generic manufacturers against brand manufacturers who hold pharmaceutical patents. Instead of fighting the suit, the patentee pays the generic manufacturer to drop the patent challenge. In exchange, the generic manufacturer agrees that the patentee can continue marketing the brand drug for a period of time. The patentee pays, and the generic manufacturer delays its attempted entry into the market.
The risk of these settlements is that a patentee may be using monopoly profits to avoid the risk that its patent will be held to be invalid or not infringed.
The Cipro court went further, crafting a “structured rule of reason” test for determining when a pay-for-delay suit imposed an unreasonable restraint on trade – a question the Supreme Court expressly left open.
Full content: Law.com
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Hess Shareholders Approve $53 Billion Merger with Chevron
May 28, 2024 by
CPI
EU Regulators Engage with Telegram as App Nears Critical Usage Threshold
May 28, 2024 by
CPI
EEX Offers Remedies to Address EU Antitrust Concerns Over Nasdaq Deal
May 28, 2024 by
CPI
BRG Expands European Competition Practice with New Expert Team in Brussels
May 28, 2024 by
CPI
UK Law Empowers Regulators to Fine Big Tech Without Court Approval
May 28, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI